HCP
VIR icon

Hexagon Capital Partners’s Vir Biotechnology VIR Stock Holding History

Hexagon Capital Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-163
Closed -$1.06K – 1655
2025
Q1 		$1.06K Hold
163
– – ﹤0.01% 1539
2024
Q4 		$1.2K Buy
163
+33
+25% +$260 ﹤0.01% 1529
2024
Q3 		$974 Sell
130
-1
-0.8% -$9 ﹤0.01% 1334
2024
Q2 		$1.17K Sell
131
-6
-4% -$58 ﹤0.01% 1245
2024
Q1 		$1.39K Sell
137
-39
-22% -$397 ﹤0.01% 1224
2023
Q4 		$1.77K Sell
176
-140
-44% -$1.28K ﹤0.01% 1152
2023
Q3 		$2.96K Sell
316
-442
-58% -$6.3K ﹤0.01% 999
2023
Q2 		$18.6K Buy
758
+82
+12% +$2.06K ﹤0.01% 581
2023
Q1 		$15.7K Sell
676
-143
-17% -$3.66K ﹤0.01% 617
2022
Q4 		$20.7K Buy
819
+356
+77% +$8.73K 0.01% 536
2022
Q3 		$9K Buy
463
+143
+45% +$3.63K ﹤0.01% 814
2022
Q2 		$8K Buy
+320
New +$7.47K ﹤0.01% 709
2022
Q1 		– Sell
-286
Closed -$12K – 991
2021
Q4 		$12K Buy
+286
New +$11.2K ﹤0.01% 586

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hexagon Capital Partners's VIR Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 163 shares — an estimated $1.06K sold.

Hexagon Capital Partners first reported a position in VIR in Q4 2021 and held it in 13 quarters. The position peaked at $20.7K in Q4 2022. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 163 Vir Biotechnology shares in Q2 2025, an estimated $1.06K.
  • Hexagon Capital Partners first reported a position in Vir Biotechnology in Q4 2021 and held it in 13 quarters.
  • Hexagon Capital Partners's Vir Biotechnology position peaked at $20.7K in Q4 2022.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.